Literature DB >> 8673983

Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society.

R C Beveridge1, A F Grunfeld, R V Hodder, P R Verbeek.   

Abstract

OBJECTIVE: To develop a set of comprehensive, standardized evidence-based guidelines for the assessment and treatment of acute asthma in adults in the emergency setting. OPTIONS: The use of medications was evaluated by class, dose, route, onset of action and optimal mode of delivery. The use of objective measurements and clinical features to assess response to therapy were evaluated in relation to the decision to admit or discharge the patient or arrange for follow-up care. OUTCOMES: Control of symptoms and disease reflected in hospital admission rates, frequency of treatment failures following discharge, resolution of symptoms and improvement of spirometric test results. EVIDENCE: Previous guidelines, articles retrieved through a search of MEDLINE, emergency medical abstracts and information from members of the expert panel were reviewed by members of the Canadian Association of Emergency Physicians (CAEP) and the Canadian Thoracic Society. Where evidence was not available, consensus was reached by the expert panel. The resulting guidelines were reviewed by members of the parent organizations. VALUES: The evidence-based methods and values of the Canadian Task Force on the Periodic Health Examination were used. BENEFITS, HARMS AND COSTS: As many as 80% of the approximate 400 deaths from asthma each year in Canada are felt to be preventable. The use of guidelines, aggressive emergency management and consistent use of available options at discharge are expected to decrease the rates of unnecessary hospital admissions and return visits to emergency departments because of treatment failures. Substantial decreases in costs are expected from the use of less expensive drugs, or drug delivery systems, fewer hospital admissions and earlier return to full activity after discharge. RECOMMENDATIONS: Beta2-agonists are the first-line therapy for the management of acute asthma in the emergency department (grade A recommendation). Bronchodilators should be administered by the inhaled route and titrated using objective and clinical measures of airflow limitation (grade A). Metered-dose inhalers are preferred to wet nebulizers, and a chamber (spacer device) is recommended for severe asthma (grade A). Anticholinergic therapy should be added to beta 2 agonist therapy in severe and life-threatening cases and may be considered in cases of mild to moderate asthma (grade A). Aminophylline is not recommended for use in the first 4 hours of therapy (grade A). Ketamine and succinylcholine are recommended for rapid sequence intubation in life-threatening cases (grade B). Adrenaline (administered subcutaneously or intravenously), salbutamol (administered intravenously) and anesthetics (inhaled) are recommended as alternatives to conventional therapy in unresponsive life-threatening cases (grade B). Severity of airflow limitation should be determined according to the forced expiratory volume at 1 second or the peak expiratory flow rate, or both, before and after treatment and at discharge (grade A). Consideration for discharge should be based on both spirometric test results and assessment of clinical risk factors for relapse (grade A). All patients should be considered candidates for systemic corticosteroid therapy at discharge (grade A). Those requiring corticosteroid therapy should be given 30 to 60 mg of prednisone orally (or equivalent) per day for 7 to 14 days; no tapering is required (grade A). Inhaled corticosteroids are an integral component of therapy and should be prescribed for all patients receiving oral corticosteroid therapy at discharge (grade A). Patients should be given a discharge treatment plan and clear instructions for follow-up care (grade C). VALIDATION: The guidelines share the same principles of those from the British Thoracic Society and the National Institutes of Health. Two specific validation initiatives have been undertaken: (a) several Canadian centres have been involved in the collection of comprehensive administrative data to assess compliance and outcome measures and (b) a survey of Canadian emergency physicians conducted to gather baseline informaton of treatment patterns, was conducted before development of the guidelines and will be repeated to re-evaluate emergency management of asthma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673983      PMCID: PMC1487869     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  142 in total

1.  Pear shaped spacer nebuhaler compared with nebulised solution for terbutaline administration in acute severe asthma.

Authors:  C R Beasley; T V O'Donnell
Journal:  N Z Med J       Date:  1985-10-09

2.  Response to frequent low doses of nebulized salbutamol in acute asthma.

Authors:  C F Robertson; F Smith; R Beck; H Levison
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

3.  Nebulized ipratropium bromide in the treatment of acute asthma.

Authors:  D H Bryant
Journal:  Chest       Date:  1985-07       Impact factor: 9.410

4.  Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma.

Authors:  D Siegel; D Sheppard; A Gelb; P F Weinberg
Journal:  Am Rev Respir Dis       Date:  1985-08

5.  Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure.

Authors:  B D Harrison; T C Stokes; G J Hart; D A Vaughan; N J Ali; A A Robinson
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

6.  A controlled trial of methylprednisolone in the emergency treatment of acute asthma.

Authors:  B Littenberg; E H Gluck
Journal:  N Engl J Med       Date:  1986-01-16       Impact factor: 91.245

7.  Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated?

Authors:  C H Fanta; T H Rossing; E R McFadden
Journal:  Am J Med       Date:  1986-01       Impact factor: 4.965

8.  Enflurane and halothane in status asthmaticus.

Authors:  M Echeverria; A W Gelb; H R Wexler; D Ahmad; P Kenefick
Journal:  Chest       Date:  1986-01       Impact factor: 9.410

9.  Use of ether in life-threatening acute severe asthma.

Authors:  C E Robertson; D Steedman; C J Sinclair; D Brown; N Malcolm-Smith
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

Review 10.  Assessing severity of adult asthma and need for hospitalization.

Authors:  K A Corre; R J Rothstein
Journal:  Ann Emerg Med       Date:  1985-01       Impact factor: 5.721

View more
  16 in total

Review 1.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

2.  Personalized action plans. How to help your patients manage their asthma.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2002-08       Impact factor: 3.275

3.  Adherence to pediatric asthma guidelines in the emergency department: a survey of knowledge, attitudes and behaviour among health care professionals.

Authors:  Sanjit Bhogal; Jean Bourbeau; David McGillivray; Andrea Benedetti; Susan Bartlett; Francine Ducharme
Journal:  Can Respir J       Date:  2010 Jul-Aug       Impact factor: 2.409

Review 4.  Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  L Fabbri; B Beghé; G Caramori; A Papi; M Saetta
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

5.  Management of acute asthma in adults in the emergency department: assisted ventilation.

Authors:  Rick Hodder; M Diane Lougheed; J Mark FitzGerald; Brian H Rowe; Alan G Kaplan; R Andrew McIvor
Journal:  CMAJ       Date:  2009-11-09       Impact factor: 8.262

Review 6.  Management of acute asthma in adults in the emergency department: nonventilatory management.

Authors:  Rick Hodder; M Diane Lougheed; Brian H Rowe; J Mark FitzGerald; Alan G Kaplan; R Andrew McIvor
Journal:  CMAJ       Date:  2009-10-26       Impact factor: 8.262

Review 7.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

8.  Impacts of a provincial asthma guidelines continuing medical education project: The Ontario Asthma Plan of Action's Provider Education in Asthma Care Project.

Authors:  M Diane Lougheed; Dilshad Moosa; Shelagh Finlayson; Wilma M Hopman; Mallory Quinn; Kim Szpiro; Joseph Reisman
Journal:  Can Respir J       Date:  2007-03       Impact factor: 2.409

9.  Asthma: Effect of genotype on Response to Therapy in the Emergency Department.

Authors:  Sean O Henderson; Vannita Simma-Chiang; Chi Lee; Kirsten Calder; Wendy J Mack
Journal:  West J Emerg Med       Date:  2007-08

10.  Increasing the use of anti-inflammatory agents for acute asthma in the emergency department: experience with an asthma care map.

Authors:  B H Rowe; A M Chahal; C H Spooner; S Blitz; A Senthilselvan; D Wilson; B R Holroyd; M Bullard
Journal:  Can Respir J       Date:  2008 Jan-Feb       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.